|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas显示文摘 | Fabbri A Cencini E Alterini R | 2014 | European Journal of Haematology2014，93，2： | 1 |
| 2 | Active and passive fields face to face 显示文摘 | CELANI A CENCINI M MAZZINO A | 2004 | New J Phys2004，6，： | 1 |
| 3 | Cag,a pathogennicity island of Helicobacter pylori,encodes type I-specific and disease-associated virulence factors显示文摘 | Cencini S Lange C Xiang ZY | 1996 | Proc Natl Sci USA1996，93，14： | 1 |
| 4 | Coexistence and invasibility in a two-species competition model with habitat-preference显示文摘 | Pigolotti S Cencini M | 2010 | Journal of Theoretical Biology2010，265，： | 1 |
| 5 | Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior显示文摘 | Forconi Francesco Sozzi Elisa Cencini Emanuele | 2009 | Blood2009，114，1： | 1 |
| 6 | Synchronization of extended chaotic systems with long-range interactions: An analogy to levy-flight spreading of epidemics显示文摘 | Tessone C J Cencini M Torcini A | 2006 | Phys Rev Lett2006，97，22： | 1 |
| 7 | Physical processes and human activities in the evolution of the Po delta, Jtaly显示文摘 | Cencini C | 1998 | Journal of Coastal Research1998，14，： | 1 |
| 8 | Drug resistance and minimal residual disease in multiple myeloma显示文摘Great progress has been made in improving survival in multiple myeloma(MM)patients over the last 30 years.New drugs have been introduced and complete responses are frequently seen.However,the majority of MM patients do experience a relapse at a variable time after treatment,and ultimately the disease becomes drug-resistant following therapies.Recently,minimal residual disease(MRD)detection has been introduced in clinical trials utilizing novel therapeutic agents to measure the depth of response.MRD can be considered as a surrogate for both progression-free and overall survival.In this perspective,the persistence of a residual therapy-resistant myeloma plasma cell clone can be associated with inferior survivals.The present review gives an overview of drug resistance in MM,i.e.,mutation ofβ5 subunit of the proteasome;upregulation of pumps of efflux;heat shock protein induction for proteasome inhibitors;downregulation of CRBN expression;deregulation of IRF4 expression;mutation of CRBN,IKZF1,and IKZF3 for immunomodulatory drugs and decreased target expression;complement protein increase;sBCMA increase;and BCMA down expression for monoclonal antibodies.Multicolor flow cytometry,or next-generation flow,and next-generation sequencing are currently the techniques available to measure MRD with sensitivity at 10-5.Sustained MRD negativity is related to prolonged survival,and it is evaluated in all recent clinical trials as a surrogate of drug efficacy. | Alessandro Gozzetti Sara Ciofini Anna Sicuranza Paola Pacelli Donatella Raspadori Emanuele Cencini Dania Tocci Monica Bocchia | 2022 | Cancer Drug Resistance2022，5，1： | 1 |
| 9 | Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single- agent cladfibine and with more aggressive behavior 显示文摘 | Forconi F Sozzi E Cencini E | 2009 | Blood2009，114，21： | 1 |
| 10 | Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma:report of a case with long-term follow-up显示文摘 | Fabbri A Cencini E Pietrini A | | 0，，04： | 1 |
| 11 | Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma:Report of a case with long-term follow-up显示文摘 | Fabbri A Cencini E Pietrini A | 2012 | Hematol Oncol2012，11，： | 1 |
| 12 | Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas显示文摘 | Fabbri A Cencini E Ahefini R | 2014 | Eur J Haematol2014，93，2： | 1 |
| 13 | Lyapunov analysis: from dynamical systems theory to applications显示文摘 | Massimo Cencini Francesco Ginelli | 2013 | Journal of Physics A: Mathematical and Theoretical2013，，25： | 1 |
| 14 | Transcribing and encoding spoken data 显示文摘 | Cencini M | 2002 | OCLC Systems and Services2002，18，4： | 1 |
| 15 | Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas显示文摘T-cell lymphomas(TCLs)represent a group of lymphoid neoplasms characterized by an aggressive clinical course,even after an anthracycline-containing regimen.Novel agents for patients with relapsed/refractory TCL are urgently needed.Lenalidomide is an oral drug with immunomodulatory,antiangiogenic and direct antineoplastic effects.These peculiar mechanisms of action make TCL an attractive target for lenalidomide.We have identified five clinical trials in which lenalidomide monotherapy was investigated to treat TCL,including cutaneous TCL(CTCL)and adult T-cell lymphoma/leukemia(ATLL).In the ATLL-002 study,the overall response rate(ORR)was 42%and median progression-free survival(PFS)and overall survival were 3.8 mo and 20.3 mo,respectively.In a phase II trial for CTCL,ORR was 28%and median PFS and overall survival were 8 mo and 43 mo,respectively.For nodal peripheral TCL,ORR was between 10%and 43%in three clinical trials,with a median PFS of about 4 mo,even if some patients had a durable response.Overall toxicity is manageable and grade 3-4 events are mainly hematological and reversible.Combination strategies did not improve PFS.In conclusion,lenalidomide could represent a suitable treatment option for relapsed/refractory TCL,especially for neoplasms with a T-follicular helper origin,such as angioimmunoblastic TCL. | Emanuele Cencini Alberto Fabbri Bianca Mecacci Monica Bocchia | 2021 | World Journal of Clinical Oncology2021，12，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员